Predictors of warfarin therapeutic dose in cancer patients: a preliminary comparative study using machine
Kannan Sridharan1, Gowri Sivaramakrishnan2, Matteo Santoni3,4
1Department of Pharmacology & Therapeutics, College of Medicine & Health Sciences, Arabian Gulf University, Manama, Kingdom of Bahrain.
Background:
Warfarin dosing in cancer patients is challenging due to altered pathophysiology and variable responses. While machine learning offers predictive potential, clinical adoption requires interpretability. This study is an initial attempt at addressing whether different dosing strategies are required in this vulnerable population.
Research Design And Methods:
This observational study analyzed 1,746 patients (124 with cancer) from the International Warfarin Pharmacogenetics Consortium database. Five machine learning algorithms were developed and compared with the best-performing model interpreted using SHAP analysis. Bayesian Additive Regression Trees provided uncertainty quantification, and the Virtual Twins method estimated cancer's individualized treatment effect on dose requirements.
Results:
Genetic variants, particularly VKORC1 and CYP2C9, dominated dose prediction in both cohorts. However, cancer introduced complexity: clinical predictors showed greater variability and prediction errors, while Bayesian analysis revealed wider uncertainty intervals for inaccurate estimates. The Virtual Twins method demonstrated substantial heterogeneity in cancer's effect, with mean individualized treatment effect of 3.35 mg/week, yet 62.5% of patients exhibited positive effects indicating higher dose requirements. These findings suggest uniform dose adjustments for cancer patients may be inappropriate.
Conclusions:
Cancer patients possibly require personalized warfarin dosing, as genetic and clinical factors interact unpredictably. Explainable artificial intelligence and Bayesian models potentially enable individualized anticoagulation in oncology.
Related Concept Videos
Therapeutic Drug Monitoring: Affecting Factors
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
